Investigational treatment improves outcomes without complete complement blockade ...

The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...

(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...

President and CEO Doug Love outlined a series of anticipated clinical and regulatory milestones during the 25th Annual ...

At UC, 70% of undergrads participate in research, creative projects or service learning. Three new programs bridge classroom ...

Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving ...

First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...

First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company ...

C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...

The MarketWatch News Department was not involved in the creation of this content. -- Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated ...

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammation MB0109 demonstrated ...